Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.

By James B. Young, W. Abraham, Andrew L. Smith, A. León, R. Lieberman, B. Wilkoff, R. Canby, J. Schroeder, L. Liem, S. Hall and 1 more. Journal of the American Medical Association (JAMA), 2003

1,712 citations recorded by the source corpus.

Subfields: General Health Professions, Philosophy

View Paper: https://www.semanticscholar.org/paper/d308e0c4efda6e8c14adb5fefb7cb1bc48ae054b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Priori
2. Douglas P. Zipes
3. Sidney C. Smith
4. Jeffrey L. Anderson
5. Rick A. Nishimura
6. A. Jacobs
7. A. Camm
8. E. Antman

Citations in the corpus

• Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. (2008, background): “The 97% implant success rate was very igh, representing an improvement in implantation techique and lead technologies compared with earlier CRT tudies (2,3).”
• ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, background): “Cardiac resynchronization therapy has been shown to improve hemodynamics, increase LVEF, extend exercise tolerance, and improve quality of life.(769,770) In patients with a poor functional status (NYHA functional class III or IV), reduced ventricular function (LVEF less than or equal to 35%), and a ”